Early Access

10-QPeriod: Q2 FY2017

MARSH & MCLENNAN COMPANIES, INC. Quarterly Report for Q2 Ended Jun 30, 2017

Filed July 28, 2017For Securities:MRSHMMC

Summary

Marsh & McLennan Companies, Inc. (MRSH) reported solid financial performance for the six months ended June 30, 2017, with consolidated revenue increasing by 4% to $7.0 billion and net income attributable to the company rising by 12% to $1.07 billion compared to the same period in 2016. Diluted earnings per share saw a corresponding increase of 13% to $2.05. The company's operating income also grew by 8% to $1.6 billion, driven by strength in both its Risk and Insurance Services and Consulting segments. The company continued its strategic growth through acquisitions, investing $412 million in the first half of 2017 across its segments. Management also demonstrated a commitment to returning capital to shareholders through significant share repurchases totaling $400 million in the first half of the year, supported by an authorized repurchase program of approximately $2.0 billion remaining as of June 30, 2017. Despite a challenging regulatory environment with ongoing investigations in the UK and Ireland, the company's core operations show resilience and growth.

Financial Statements
Beta
Revenue$3.50B
Operating Expenses$2.79B
Operating Income$701.00M
Interest Expense$60.00M
Net Income$501.00M
EPS (Basic)$0.98
EPS (Diluted)$0.96
Shares Outstanding (Basic)514.00M
Shares Outstanding (Diluted)520.00M

Key Highlights

  • 1Consolidated revenue increased by 4% to $7.0 billion for the first six months of 2017 compared to the prior year.
  • 2Net income attributable to the Company grew by 12% to $1.07 billion for the first six months of 2017.
  • 3Diluted earnings per share increased by 13% to $2.05 for the first six months of 2017.
  • 4Operating income rose by 8% to $1.6 billion for the first six months of 2017.
  • 5The company completed several strategic acquisitions, investing $412 million in the first half of 2017.
  • 6Share repurchases totaled $400 million in the first six months of 2017, with $2.0 billion remaining authorization.
  • 7The company is subject to ongoing regulatory investigations in the UK and Ireland concerning potential anti-competitive practices.

Frequently Asked Questions